William Blair Analysts Raise Earnings Estimates for Inogen Inc (INGN)
Inogen Inc (NASDAQ:INGN) – Stock analysts at William Blair lifted their Q1 2018 earnings per share estimates for shares of Inogen in a research note issued on Wednesday. William Blair analyst M. Kaczor now forecasts that the medical technology company will post earnings of $0.27 per share for the quarter, up from their previous estimate of $0.22. William Blair also issued estimates for Inogen’s Q4 2018 earnings at $0.41 EPS, FY2018 earnings at $1.68 EPS, Q1 2019 earnings at $0.33 EPS and Q2 2019 earnings at $0.53 EPS.
INGN has been the topic of a number of other research reports. Zacks Investment Research cut shares of Inogen from a “buy” rating to a “hold” rating in a research note on Wednesday, January 10th. BidaskClub cut shares of Inogen from a “hold” rating to a “sell” rating in a research note on Saturday, January 6th. Piper Jaffray Companies upgraded shares of Inogen from a “neutral” rating to an “overweight” rating in a research note on Tuesday, February 20th. Needham & Company LLC lifted their target price on shares of Inogen from $125.00 to $150.00 and gave the company a “strong-buy” rating in a research note on Wednesday. Finally, Leerink Swann reiterated an “outperform” rating and issued a $120.00 price target (up previously from $115.00) on shares of Inogen in a research note on Wednesday, November 8th. Three analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $107.29.
In other Inogen news, insider Scott Wilkinson sold 30,651 shares of the business’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $115.75, for a total value of $3,547,853.25. Following the sale, the insider now owns 38,107 shares in the company, valued at approximately $4,410,885.25. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Alison Bauerlein sold 27,630 shares of the business’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $116.46, for a total transaction of $3,217,789.80. Following the completion of the sale, the executive vice president now owns 11,718 shares in the company, valued at approximately $1,364,678.28. The disclosure for this sale can be found here. In the last quarter, insiders sold 167,458 shares of company stock worth $19,885,478. Corporate insiders own 5.31% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the company. California Public Employees Retirement System raised its position in shares of Inogen by 31.2% during the 3rd quarter. California Public Employees Retirement System now owns 26,498 shares of the medical technology company’s stock valued at $2,520,000 after buying an additional 6,298 shares in the last quarter. Quantbot Technologies LP raised its position in shares of Inogen by 74.1% during the 3rd quarter. Quantbot Technologies LP now owns 9,665 shares of the medical technology company’s stock valued at $919,000 after buying an additional 4,112 shares in the last quarter. Allianz Asset Management GmbH raised its position in shares of Inogen by 3.8% during the 3rd quarter. Allianz Asset Management GmbH now owns 40,629 shares of the medical technology company’s stock valued at $3,864,000 after buying an additional 1,490 shares in the last quarter. Sumitomo Mitsui Asset Management Company LTD purchased a new stake in shares of Inogen during the 4th quarter valued at about $1,776,000. Finally, Ameriprise Financial Inc. raised its position in shares of Inogen by 6.0% during the 3rd quarter. Ameriprise Financial Inc. now owns 187,068 shares of the medical technology company’s stock valued at $17,781,000 after buying an additional 10,669 shares in the last quarter.
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.